Plasma Biomarker Characterization of Alzheimer’s Disease Psychosis in Study ACP‐204‐006
Biomarkers, rather than syndromic presentation, are recommended as a mechanism by which to define AD biologically. Since biomarker data from patients presenting with clinical symptoms consistent with Alzheimer's disease dementia and psychosis are sparse, we present biomarker data in a rigorously phenotyped population. These results can also inform the design and execution of clinical trials in ADP in the future.
Authors
- Becky Howell
- Bryan Dirks (ORCID: https://orcid.org/0000-0001-6472-1606)
- Sanjeev Pathak (ORCID: https://orcid.org/0000-0003-1565-2223)
- Samantha Friend
- Xiaoshu Feng
- Peter M Zhang
- Christine M Murphy
Institutions
- Acadia Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_106556
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00